Evidence map›Paper›PMID 29802636›Full record

ArticleDiabetic medicine : a journal of the British Diabetic Association2018

The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis.

S Heller, K Bowering, P Raskin, A Liebl, K Buchholtz, A Gorst-Rasmussen, T R Pieber

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetic medicine : a journal of the British Diabetic Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01850615 (Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01850615 phase3completednot on this map

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

TypeinterventionalSponsorNovo Nordisk A/SRan2013 to 2014Enrolled323ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsFaster-acting insulin aspart, basal insulin
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

S HellerAcademic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK.ORCID http://orcid.org/0000-0002-2425-9565
K BoweringDivision of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.ORCID http://orcid.org/0000-0002-0075-0624
P RaskinUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.
A LieblCenter for Diabetes and Metabolism, m&i-Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany.
K BuchholtzNovo Nordisk A/S, Søborg, Denmark.
A Gorst-RasmussenNovo Nordisk A/S, Søborg, Denmark.
T R PieberDivision of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo investigate the impact of baseline 1,5-anhydroglucitol on the treatment effect of basal-bolus therapy in people with Type 2 diabetes.

methodsPost hoc analysis of onset 3, an 18-week, randomized, phase 3 trial evaluating the efficacy and safety of fast-acting insulin aspart in basal-bolus therapy (n = 116) vs. basal insulin-only therapy (n = 120) in people with Type 2 diabetes. The estimated treatment difference in change from baseline in HbA

resultsThe estimated treatment difference in change from baseline in HbA

conclusionThis analysis indicates that people with Type 2 diabetes with low 1,5-anhydroglucitol have an added treatment benefit with basal-bolus therapy compared with people with higher 1,5-anhydroglucitol. Further research is needed to clarify any clinical utility of these findings. Clinical Trials Registry No: NCT01850615.

Identifiers

PMID29802636
PMCPMC6099439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.